Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Luckily for you, StockStory helps you navigate which companies are truly worth holding. Keeping that in mind, here is one low-volatility stock that could succeed under all market conditions and two that may not keep up.
Two Stocks to Sell:
Moderna (MRNA)
Rolling One-Year Beta: 0.05
Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ: MRNA) develops messenger RNA (mRNA) medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases.
Why Are We Out on MRNA?
- Annual sales declines of 20.5% for the past five years show its products and services struggled to connect with the market during this cycle
- Sales were less profitable over the last five years as its earnings per share fell by 24.5% annually, worse than its revenue declines
- 95.9 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
Moderna is trading at $189.57 per share, or 36.8x forward price-to-sales. Read our free research report to see why you should think twice about including MRNA in your portfolio.
Artivion (AORT)
Rolling One-Year Beta: 0.28
Formerly known as CryoLife until its 2022 rebranding, Artivion (NYSE: AORT) develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease.
Why Do We Think Twice About AORT?
- Smaller revenue base of $471.5 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Negative free cash flow raises questions about the return timeline for its investments
- Underwhelming 2.4% return on capital reflects management’s difficulties in finding profitable growth opportunities
Artivion’s stock price of $22.30 implies a valuation ratio of 44.2x forward P/E. Check out our free in-depth research report to learn more about why AORT doesn’t pass our bar.
One Stock to Watch:
ePlus (PLUS)
Rolling One-Year Beta: 0.51
Starting as a financing company in 1990 before evolving into a full-service technology provider, ePlus (NASDAQ: PLUS) provides comprehensive IT solutions, professional services, and financing options to help organizations optimize their technology infrastructure and supply chain processes.
Why Are We Fans of PLUS?
- 8.5% annual revenue growth over the last five years surpassed the sector average as its services resonated with customers
- Free cash flow margin increased by 6.3 percentage points over the last five years, giving the company more capital to invest or return to shareholders
- Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures
At $93.47 per share, ePlus trades at 16.8x forward P/E. Is now a good time to buy? See for yourself in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
